EMA Authorised: Teriflunomide Viatris (previously Teriflunomide Mylan) (teriflunomide) — Viatris Limited

View source ↗

Summary

Teriflunomide Viatris has been authorised for relapsing-remitting multiple sclerosis in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Teriflunomide Viatris (teriflunomide)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis, Relapsing-Remitting. MAH: Viatris Limited. Decision date: 21/05/2026